BioWorld

July 8, 2003

RNAi Companies Ribopharma, Alnylam Merge, Raise $24.6M

A hot young section of the industry is seeing some consolidation already, as Alnylam Pharmaceuticals Inc. merged with its counterpart in Germany, Ribopharma AG, and concurrently raised $24.6 million in private financing to build a bigger, stronger entity. (BioWorld Today) Read More

Cellegy Stock Slides After FDA Issues Non-Approvable Letter

Second-Harmonic Generation, Birth-Easing Relaxin Hormone Hurry Cancer Drugs To Targets

BioMarin Set To Start Phase III With Enzyme Therapy Aryplase

NexMed Raises $10.5M Through Private Sale Of Common Shares

Merck Seeks European Marketing Approval For Cancer Drug Erbitux

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...